Myeloma 2015 | Emerging monoclonal antibodies for the treatment of multiple myeloma

Rafael Fonseca

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses novel monoclonal antibodies (mAbs) for the treatment of multiple myeloma. Anti-CD38 mAbs and elotuzumab are showing promising activity in clinical development.

Share this video  
Similar topics
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
Antibodies, Elotuzumab
Myeloma 2015
11th April 2015
More from Rafael Fonseca
A pharmacoeconomic analysis of multiple myeloma treatment
Applying myeloma knowledge in lymphoma
Transplant vs bortezomib and LEN/DEX in multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals